OncoMatch/Clinical Trials/NCT06510361
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Is NCT06510361 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Epcoritamab for lymphoma.
Treatment: Epcoritamab — This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive (by immunophenotype or immunohistochemistry) at time of diagnosis (all degrees of CD20 positivity accepted)
follicular lymphoma grade 1-3A that is CD20+ (by immunophenotype or immunohistochemistry) at time of diagnosis. All degrees of CD20 positivity will be accepted.
Disease stage
Required: Stage III, IV
Grade: 123a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody combined with chemotherapy (obinutuzumab, rituximab, bendamustine, CHOP, CVP, lenalidomide) — upfront or first-line
1 prior line (at least 3 cycles) of systemic "upfront" or first-line therapy consisting of anti-CD20 antibody (e.g. obinutuzumab or rituximab) combined with chemotherapy (e.g. bendamustine, CHOP, CVP, or lenalidomide). Rituximab monotherapy, rituximab plus radiation, or radiation alone is not sufficient.
Cannot have received: rituximab monotherapy (rituximab)
Rituximab monotherapy, rituximab plus radiation, or radiation alone is not sufficient.
Cannot have received: investigational agent
Use of investigational agents incorporated into prior induction therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥1000 cells/mcl (G-CSF allowed if marrow involved); Platelets ≥75,000 cells/mcl (transfusion allowed if marrow involved); Hemoglobin ≥ 8 g/dL (transfusion allowed if marrow involved)
Kidney function
Creatinine ≤ institutional ULN OR creatinine clearance > 45 ml/min (by Cockcroft-Gault estimate or 24-hr creatinine clearance measurement)
Liver function
Total bilirubin ≤ 1.5 institutional ULN (≤3x ULN if Gilbert's disease); AST(SGOT)/ALT(SGPT) ≤3× institutional ULN unless suspected/known involvement by follicular lymphoma
Cardiac function
EF ≥45%
Participants must meet the following organ and marrow function as defined below: Absolute neutrophil count ≥1000 cells/mcl (G-CSF allowed if marrow involved with disease); Platelets ≥75,000 cells/mcl (transfusion allowed if marrow involved); Hemoglobin ≥ 8 g/dL (transfusion allowed if marrow involved); Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN). In patients with suspected/known Gilbert's disease total bilirubin up to 3x ULN will be allowed; AST(SGOT)/ALT(SGPT) ≤3× institutional ULN unless suspected/known involvement by follicular lymphoma; Creatinine ≤ institutional ULN OR creatinine clearance > 45 ml/min (by Cockcroft-Gault estimate or 24-hr creatinine clearance measurement); EF <45% or need for supplemental O2 at rest to maintain SaO2>89% [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford · Stanford, California
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Icahn School of Medicine at Mount Sinai · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify